hotspot -WSS

hotspot

author：hotspot 2025-09-29 21:27:30 - browse：467

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Can U.S. cancer drug shortages be fixed?

knowledge

WSS

CDC says it’s too soon to assess risk posed by Covid subvariant

FDA advisory panel to debate high blood pressure devices

Louisiana bill approved classifying abortion pills as controlled substances

Lawsuit challenges CMS nursing home minimum staffing rule

As obesity drug market grows, telehealth companies court payers

Unmasking the 'centricity' illusion in clinical trials

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

J&J reports mixed data on next

Duchenne breakthrough therapy leaves behind pioneering families

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why we need mandatory labeling of GMO products

Wildfire smoke exposes gaps in outdoor worker protections

People can get long Covid without testing positive for virus: Study

Peter Hotez and the public health issue of online harassment

The world needs the new pandemic treaty

focus

Decentralized clinical trials need collaboration to achieve wider use

How the first Native Hawaiian psychiatrist helped diversify medicine

As obesity drug market grows, telehealth companies court payers

Clinicians often fail to acknowledge the pain caused by long Covid

Study: Spinal cord stimulation helps patients with paralysis walk again

Study: Spinal cord stimulation helps patients with paralysis walk again

focus

hotspot

knowledge

hotspot